Latest

• Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017

  Public drug plan coverage is low, slow and inconsistent: bad news for patients, Pharmacare and pCPA. »

• Coverage of new medicines in public versus private drug plans in Canada 2008-2017

  Experience forewarns that National Pharmacare will reduce access to medicines. »

• Medical devices spending in Canada 2013-2017

  Is Canada under-investing in the adoption and use of medical devices? »

• Prescription drug plan coverage 2016: how many Canadians were insured, under-insured or uninsured?

  Advocates for pharmacare claim that millions of Canadians are not covered by any type of drug plan. But is it true? »

• Comparing expert representation on HTA advisory committees in Canada, the UK and Australia

  Are there expertise gaps on Canada’s HTA advisory committees? »

• Consequences of over-regulating the prices of new drugs in Canada

  Can the federal government preserve the availability of new medicines for Canadian patients while further depressing the prices of patented drugs? »

• Facts about the cost of patented drugs in Canada

  If governments are going to cite the cost of patented drugs to justify their policies, they should, at least, get the basic facts correct. »

• Costs without benefits for patients? Non-medical spending in Canada’s public health system

  Evidence suggests that billions of dollars are potentially being squandered annually on non-medical expenses without any demonstrable benefits for patients. »

• Does Canada need a Patented Medicine Prices Review Board?

  How will patients and taxpayers be impacted by the proposed changes to price regulations for new drugs? »